The folate receptor (FR) is a recognised biomarker for tumour cells due to its overexpression
on a large number of tumours. Consequently, the FR has been exploited by many diagnostic …

Epithelial ovarian cancer is the commonest cause of gynaecological cancer-associated
death. The disease typically presents in postmenopausal women, with a few months of …

Purpose This randomized, multicenter, phase III noninferiority trial was designed to test the
efficacy and safety of the combination of pegylated liposomal doxorubicin (PLD) with …

Background The role of cytoreductive surgery in relapsed ovarian cancer is not clearly
defined. Therefore, patient selection remains arbitrary and depends on the center's …

More than 90% of ovarian cancers have been thought to arise from epithelial cells that cover
the ovarian surface or, more frequently, line subserosal cysts. Recent studies suggest that …

Background: The CALYPSO phase III trial compared CD (carboplatin-pegylated liposomal
doxorubicin (PLD)) with CP (carboplatin-paclitaxel) in patients with platinum-sensitive …

Background The standard management of primary ovarian cancer is optimal cytoreductive
surgery followed by platinum‐based chemotherapy. Most women with primary ovarian …

Recurrent ovarian cancer is a lethal disease, and few patients can be cured. Although most
patients receive standardized surgery and chemotherapy, the status of recurrent disease is …

Question What is the optimal chemotherapy treatment for women with recurrent ovarian
cancer who have previously received platinum-based chemotherapy? Perspectives …

OBJECTIVE: Farletuzumab is a humanized monoclonal antibody to folate receptor-α, which
is over-expressed in most epithelial ovarian cancers but largely absent on normal tissue. We …